Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements (indications and TB evaluation; infection risk framing) align with the provided label excerpts. However, multiple claims about blood-test monitoring being clinician-chosen, baseline/ongoing CBC/LFT/renal testing, and adjusting/pausing based on abnormal blood counts or liver tests are not supported by the supplied label text and appear speculative or overly generalized relative to the excerpts provided.
Category Scores
Accurate Statements
Cosentyx is indicated for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis (with additional listed indications in the label).
SECTION 1.1 Plaque Psoriasis; SECTION 1.2 Psoriatic Arthritis; SECTION 1.3 Ankylosing Spondylitis
Evaluate for active or latent tuberculosis prior to initiating Cosentyx; initiation is not recommended in patients with active TB infection and latent TB should be treated prior to starting.
SECTION 2.1 Testing and Procedures Prior to Treatment Initiation; SECTION 5.3 Pre-Treatment Evaluation for Tuberculosis
Unsupported Statements
There is not one single universal blood-test monitoring plan for Cosentyx; the blood-test schedule is set by the prescribing clinician and depends on diagnosis and other medicines.
The provided label excerpts do not state that there is no universal blood-test monitoring plan or that clinicians set a blood-test schedule based on diagnosis/other medicines.
Clinicians commonly order periodic blood tests during Cosentyx treatment to watch for effects that could be related to infection risk and to check baseline/ongoing safety in people with comorbidities or prior blood abnormalities.
The supplied label excerpts discuss infection risk and specific pre-treatment evaluations (e.g., TB), but do not describe routine periodic blood testing to monitor infection risk or safety in comorbidities/prior blood abnormalities.
The blood-test schedule for Cosentyx is influenced by whether the patient takes other immunosuppressive drugs.
No such statement is present in the provided label excerpts.
Baseline monitoring for Cosentyx often includes a full blood count (FBC/CBC).
Not supported by the provided label excerpts.
Baseline monitoring for Cosentyx often includes liver function tests.
Not supported by the provided label excerpts.
Baseline monitoring for Cosentyx often includes kidney function tests.
Not supported by the provided label excerpts.
Baseline monitoring for Cosentyx often includes infection screening, particularly tuberculosis and hepatitis status before starting biologic therapy.
TB evaluation is supported; however, hepatitis status screening prior to starting is not specifically supported in the provided excerpts (hepatitis B reactivation is mentioned as a warning, but pre-treatment screening/testing is not specified here).
During Cosentyx treatment, follow-up blood tests are typically repeated at intervals chosen by the prescriber.
Not supported by the provided label excerpts.
Follow-up blood testing may be more frequent if the patient has risk factors, abnormal prior results, or is taking other systemic therapies.
Not supported by the provided label excerpts.
Monitoring can be more frequent if Cosentyx is used alongside other agents that affect blood counts or liver function.
Not supported by the provided label excerpts.
If the patient also takes methotrexate, corticosteroids, or other immunosuppressants, the clinician may test more often to keep track of combined effects.
Although methotrexate co-administration is addressed for PsA dosing, the provided excerpts do not state that monitoring frequency (blood tests) increases due to combined effects.
If blood counts or liver tests are abnormal, the clinician may repeat the test sooner to confirm the result.
Not supported by the provided label excerpts.
If blood counts or liver tests are abnormal, the clinician may adjust or pause treatment.
The provided label excerpts do not describe treatment adjustment/pause specifically based on blood counts or liver test abnormalities.
If blood counts or liver tests are abnormal, the clinician may check for infection or other causes.
Not supported by the provided label excerpts.
If the patient develops signs of infection (such as fever, persistent cough, or feeling unwell), clinicians often reassess treatment and may order blood tests urgently rather than on the routine schedule.
The label excerpts discuss infection risk and TB evaluation/monitoring generally, but do not support that clinicians order urgent blood tests in response to specific infection symptoms or that blood tests are ordered rather than routine schedule.
Contradictions
Important Omissions
No boxed warning content was evaluated because the provided label excerpts do not include any boxed warning section; additionally, specific label-backed contraindications (e.g., serious hypersensitivity) were not addressed in the AI claims.
Importance:
Moderate
The label excerpt emphasizes TB evaluation and latent TB management prior to initiation; the AI claims heavily emphasize broad blood-test monitoring (CBC/LFT/renal) that is not shown in the provided excerpts, suggesting a material mismatch/overreach. A label-consistent monitoring section (e.g., TB monitoring during/after treatment) was not accurately reflected for all monitoring assertions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overgeneralized or unsupported assertions about routine blood-count/LFT/renal monitoring and actions (repeat/adjust/pause) based on abnormal blood tests could mislead readers about label-supported monitoring requirements. However, the key supported safety element (TB evaluation prior to initiation) is included.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple monitoring-related claims (routine CBC/LFT/renal testing, frequency determined by prescriber/other immunosuppressants, and treatment changes based on abnormal blood tests) are not supported by the provided COSENTYX label excerpts.
Suggested Improvement
Limit monitoring statements to those explicitly supported in the provided label excerpts (e.g., TB evaluation prior to initiation; avoid use in active TB; treat latent TB; monitor during/after treatment) and remove or rephrase broad, unspecified blood-test schedules and blood-test-based decision rules unless supported by additional label text.